Concepedia
Statistics
Publications
21
Citations
440
H-Index
13
Active since
2013
Affiliations
Central South University(Current)
Second Xiangya Hospital of Central South University
University of Tasmania
Monash University
Lidan Yi is an author at Central South University specializing in oncology, pharmacy, and cost-effectiveness analysis.
Publications per year
2013–2024
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Qiao Liu, Xia Luo, Liubao Peng et al. · Clinical Drug Investigation · 2019 · 47 citations · Full text
Pharmacy, Oncology, Pharmacoeconomics +17
First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
Qiao Liu, Xia Luo, Lidan Yi et al. · Frontiers in Oncology · 2021 · 37 citations · Full text
Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives
Yingjie Zhang, Xiaohui Zeng, Haijun Deng et al. · Clinical Therapeutics · 2019 · 33 citations
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Peng Ye, Xiaohui Zeng, Liubao Peng et al. · Frontiers in Pharmacology · 2022 · 33 citations · Full text
First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
Peng Ye, Xiaohui Zeng, Liubao Peng et al. · Advances in Therapy · 2021 · 31 citations
Pharmacy, Oncology, Pharmacotherapy +11
1–5 of 21